Prospective study evaluating olfactometric and rhinomanometric outcomes in postmenopausal women on 1 mg 17β-estradiol and 2 mg drospirenone HT

被引:20
|
作者
Caruso, Salvatore [1 ,2 ]
Serra, Agostino [3 ]
Grillo, Calogero [3 ]
De Leo, Vincenzo [4 ]
Maiolino, Luigi [3 ]
Agnello, Carmela [2 ]
Cianci, Antonio [1 ]
机构
[1] Univ Catania, Dept Microbiol Sci & Gynecol Sci, Catania, Italy
[2] Univ Catania, Res Grp Sexol, Sect Dept Gynecol Sci, Catania, Italy
[3] Univ Catania, Dept Otorhinolaryngol, Catania, Italy
[4] Univ Siena, Dept Gynecol & Obstet, I-53100 Siena, Italy
关键词
drospirenone; hormone therapy; menopause; olfactometric threshold; rhinomanometry;
D O I
10.1097/gme.0b013e31816be973
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To evaluate the effects of drospirenone oil the olfactory sensitivity in postmenopausal women treated with hormone therapy (HT). Design: Forty-seven naturally postmenopausal women participated in the prospective study. The women Underwent continuous combined HT containing 1 mg 17 beta-estradiol and 2 mg drospirenone (DRSP). Airflow resistance values and olfactometric thresholds were measured by using rhinomanomety and olfactometry, respectively, performed at baseline and in the third and sixth cycle of HT. Results: Rhinomanometric values were better during 17 beta-estradiol/DRSP HT with respect to those observed at baseline (P < 0.001). Olfactometric threshold data indicated a higher sensitivity during both the third (P < 0.05), and sixth cycles of 17 beta-estradiol/DRSP HT (P < 0.001) than at baseline. Conclusions: Our study confirmed that the nasal airflow resistance and olfactory thresholds to odors may depend on steroid hormones. We believe that estrogens could influence neuronal plasticity and the neuronal conduction time in the olfactory system. The antimineralocorticoid activity of DRSP may produce a decrease in nasal edema, inducing a better interaction between odorous substances with receptors.
引用
收藏
页码:967 / 972
页数:6
相关论文
共 50 条
  • [1] Characteristics of nasal epithelial cells in naturally postmenopausal women receiving hormone therapy with 1 mg 17β-estradiol and 2 mg drospirenone:: a prospective study
    Caruso, Salvatore
    Serra, Agostino
    Grillo, Calogero
    Maiolino, Luigi
    Agnello, Carmela
    Di Mari, Lucia
    Cianci, Antonio
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2008, 15 (05): : 963 - 966
  • [2] Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women
    Lin, S-Q.
    Sun, L-Z.
    Lin, J-F.
    Yang, X.
    Zhang, L-J.
    Qiao, J.
    Wang, Z-H.
    Xu, Y-X.
    Xiong, Z-A.
    Zhou, Y-Z.
    Wang, M-L.
    Zhu, J.
    Chen, S-R.
    Su, H.
    Yang, C-S.
    Wang, S-H.
    Zhang, Y-Z.
    Dong, X-J.
    CLIMACTERIC, 2011, 14 (04) : 472 - 481
  • [3] Efficacy and safety of drospirenone 2 mg/17 β-estradiol 1 mg hormone therapy in Korean postmenopausal women (vol 60, pg 213, 2017)
    Park, Bo Ra
    Park, Hye Na
    Jung, Ji Back
    Lee, Eun Sil
    Kim, Jeong Sig
    Choi, Gyu Yeon
    Lee, Jeong Jae
    Lee, Im Soon
    OBSTETRICS & GYNECOLOGY SCIENCE, 2024, 67 (04) : 430 - 430
  • [4] Effects of hormone therapy containing 2 mg drospirenone and 1 mg 17β-estradiol on postmenopausal exacerbation of Meniere's disease: Preliminary study
    Grillo, Caterina Maria
    Maiolino, Luigi
    Rapisarda, Agnese Maria Chiara
    Caruso, Giuseppe
    Palermo, Gaia
    Caruso, Salvatore
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 22 (04)
  • [5] One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women
    Genazzani, A. R.
    Schmelter, T.
    Schaefers, M.
    Gerlinger, C.
    Gude, K.
    CLIMACTERIC, 2013, 16 (04) : 490 - 498
  • [6] 17β-oestradiol (1 mg) plus drospirenone (2 mg) in hormonal therapy of postmenopausal period
    Stachowiak, Grzegorz
    Pertynski, Tomasz
    MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2010, 9 (01): : 1 - 4
  • [7] A prospective study evidencing rhinomanometric and olfactometric outcomes in women taking oral contraceptives
    Caruso, S
    Grillo, C
    Agnello, C
    Maiolino, L
    Intelisano, G
    Serra, A
    HUMAN REPRODUCTION, 2001, 16 (11) : 2288 - 2294
  • [8] AN ECONOMIC EVALUATION OF DROSPIRENONE 2 MG/ESTRADIOL 1.033 MG VERSUS TIBOLONE 2.5MG IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH GRADE 1 OR 2 HYPERTENSION IN KOREA
    Jung, S.
    Watson, P. R.
    Asukai, Y.
    Jeong, M.
    VALUE IN HEALTH, 2009, 12 (07) : A293 - A293
  • [9] Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: A double-blind, randomized, placebo-controlled, multicenter study
    Lee, B. S.
    Kang, B. M.
    Yoon, B. K.
    Choi, H.
    Park, H. M.
    Kim, J. G.
    MATURITAS, 2007, 57 (04) : 361 - 369
  • [10] Olfactometric and rhinomanometric outcomes in post-menopausal women treated with hormone therapy: a prospective study
    Caruso, S
    Grillo, C
    Agnello, C
    Di Mari, L
    Farina, M
    Serra, A
    HUMAN REPRODUCTION, 2004, 19 (12) : 2959 - 2964